Physician profile
Ryan D Arnold
NPI 1659432318
$8,660.79
in general payments reported to CMS, 2019-2025
40 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $464 · 2021: $1,168 · 2022: $1,241 · 2023: $1,336 · 2024: $2,258 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,140.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $976.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $952.17 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $582.63 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals Lp | $527.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $522.89 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $460.14 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $426.94 | 2020-2025 | Linzess |
| Pfizer INC. | $383.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $372.90 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Supernus Pharmaceuticals, INC. | $285.27 | 2024-2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.89 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $249.76 | 2019-2025 | Rexulti |
| Abbott Laboratories | $171.49 | 2022-2025 | Freestyle Libre, Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $165.60 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.